TG Therapeutics, Inc.
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituxima…
Biotechnology
US, New York [HQ]
Ratios
15 Sheets · Starting from 2023Margins, Growth Rates In %
| Ratio | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||||||||
| Gross Margin | - - | - - | - - | 100.00 | 100.00 | 100.00 | 100.00 | 58.68 | 45.95 | 42.11 | -85.53 | -146.05 | 88.19 | 90.48 | 93.77 | |
| Profit Margin | - - | - - | - - | -94,879.88 | -13,438.82 | -36,606.45 | -41,310.04 | -51,353.45 | -77,749.86 | -114,132.89 | -117,991.45 | -188,077.63 | -5,315.47 | -7,318.89 | 5.42 | |
| Operating Margin | - - | - - | - - | -141,196.45 | -15,071.43 | -36,566.96 | -41,461.87 | -51,823.47 | -77,904.56 | -114,736.84 | -111,220.39 | -179,996.05 | -5,154.28 | -6,924.20 | 8.83 | |
|
EPS Growth
|
34.57 | 114.10 | -102.81 | -213.64 | 41.30 | -102.47 | 15.85 | -15.94 | -19.38 | -20.42 | 11.74 | -22.17 | -8.47 | 43.87 | 105.91 | |
| EPS USD | -11,124.00 | 1,568.00 | -44.00 | -138.00 | -81.00 | -164.00 | -138.00 | -160.00 | -191.00 | -230.00 | -203.00 | -248.00 | -269.00 | -151.00 | 8.93 | |
| Return on Assets (ROA) | -763.90 | 3.35 | -5.36 | -81.87 | -42.56 | -64.30 | -55.47 | -142.85 | -121.66 | -207.47 | -110.02 | -45.69 | -93.66 | -105.30 | 3.84 | |
| Return on Equity (ROE) | 41.17 | -11.63 | -8.86 | -116.22 | -51.13 | -69.64 | -61.97 | -218.17 | -176.85 | -721.76 | 25.58 | -55.05 | 26.76 | 13.35 | 7.90 | |
| Return on Invested Capital (ROIC) | 49.79 | -44.41 | -5.83 | -145.60 | -49.45 | -69.40 | -61.84 | -217.73 | -176.51 | -719.73 | 26.56 | -49.87 | 28.18 | 13.72 | 7.64 | |
| Solvency | ||||||||||||||||
| Equity Ratio | -1,800 | - - | - - | - - | - - | - - | - - | - - | - - | - - | -400 | - - | -300 | -700 | - - | |
| Debt/Assets | 531.45 | 100.94 | 30.71 | 14.30 | 1.54 | 0.32 | 0.19 | 0.13 | 0.13 | 0.08 | 25.03 | 6.71 | 20.82 | 42.91 | 30.82 | |
| Debt/Equity | -28.64 | -350.68 | 50.75 | 20.30 | 1.85 | 0.34 | 0.21 | 0.19 | 0.19 | 0.28 | -5.82 | 8.08 | -5.95 | -5.44 | 63.28 | |
| Debt/EBITDA | -159.65 | -340.99 | 551.50 | 55.78 | 237.59 | 101.07 | 88.50 | 31.61 | 47.67 | 24.03 | 42.86 | 187.31 | 64.19 | 10.23 | 84.83 | |
|
Debt/Capitalization
|
-40.14 | 139.89 | 33.67 | 16.88 | 1.82 | 0.34 | 0.21 | 0.19 | 0.19 | 0.28 | -6.18 | 7.48 | -6.33 | -5.75 | 38.76 | |
| Long-Term Debt/Capitalization | -10.94 | 147.08 | 29.39 | 13.75 | 0.16 | - - | - - | - - | - - | - - | -5.92 | 3.37 | -6.12 | -5.64 | 38.42 | |
| Interest Debt per Share USD | 99.23 | 504.87 | 2.54 | 0.31 | 0.07 | 0.04 | 0.03 | - - | - - | - - | 0.52 | 0.42 | 0.64 | 0.69 | 0.80 | |
| Debt Growth | 54.31 | 868.02 | -74.04 | -35.37 | -76.49 | -62.93 | -23.13 | -67.44 | 85.28 | -47.50 | 60,801.49 | 2.87 | 88.32 | 5.08 | 33.39 | |
| Liquidity | ||||||||||||||||
| Current Ratio | 10.41 | 26.39 | 612.30 | 833.72 | 669.65 | 1,663.97 | 825.13 | 301.36 | 333.79 | 203.41 | 176.62 | 698.70 | 506.19 | 316.30 | 591.85 | |
| Quick Ratio | 0.71 | 21.96 | 606.87 | 742.58 | 719.60 | 1,539.90 | 735.28 | 266.43 | 303.41 | 177.33 | 166.30 | 691.49 | 483.53 | 303.90 | 500.00 | |
| Cash Ratio | 0.71 | 14.53 | 606.87 | 742.58 | 640.88 | 1,087.91 | 522.98 | 148.30 | 202.87 | 107.99 | 133.38 | 632.11 | 457.13 | 192.30 | 173.00 | |
| Operating Cash Flow Ratio | - - | - - | - - | -200 | -100 | -600 | -400 | -300 | -300 | -300 | -100 | -200 | -400 | -300 | - - | |
| Turnover | ||||||||||||||||
| Inventory Turnover | - - | - - | - - | - - | - - | - - | - - | 1.13 | 1.04 | 0.91 | - - | - - | -3.35 | - - | 36.55 | |
| Receivables Turnover | - - | - - | - - | - - | 560.86 | 178.19 | 81.92 | 181.73 | 140.49 | 160.00 | - - | - - | 481.57 | - - | 457.33 | |
| Payables Turnover | - - | - - | - - | - - | - - | - - | - - | 0.41 | 0.32 | 0.24 | 0.94 | 1.01 | -172.87 | 0.63 | 37.83 | |
|
Asset Turnover
|
- - | - - | - - | 0.09 | 0.32 | 0.18 | 0.13 | 0.28 | 0.16 | 0.18 | 0.09 | 0.02 | 1.76 | 1.44 | 70.90 | |
| Fixed Turnover | - - | - - | - - | 1,636.43 | 2,664.94 | 748.54 | 323.38 | 6.43 | 5.69 | 5.97 | 1.29 | 1.28 | 60.44 | 25.73 | 2,868.78 | |
| Coverage | ||||||||||||||||
| Interest Coverage | -323.07 | -158.67 | -12,427.42 | -2,969.39 | -2,410.15 | -5,987.00 | -6,495.08 | - - | - - | - - | -3,197.56 | -4,322.86 | -6,115.11 | -1,892.25 | 163.56 | |
| Asset Coverage | - - | - - | 100 | 500 | 5,700 | 29,700 | 48,700 | 55,100 | 54,500 | 66,900 | 100 | 1,300 | 400 | 100 | 200 | |
| Cash Flow Coverage (CFGR) | -54.02 | -10.47 | -1.77 | -164.34 | -1,458.19 | -12,740.26 | -21,125.26 | -89,424.80 | -73,474.35 | -192,425.37 | -325.47 | -511.02 | -374.00 | -212.10 | -30.93 | |
| EBITDA Coverage | -200 | -400 | -12,400 | -2,600 | -1,700 | -5,800 | -6,300 | - - | - - | - - | -3,100 | -4,300 | -6,000 | -1,800 | 100 | |
| Dividend Coverage | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Time Interest Earned (TIE) | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | 100 | |
| Market Prospects | ||||||||||||||||
| Dividend Yield | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Earnings Yield | -49.44 | 30.97 | -39.19 | -37.86 | -20.66 | -10.34 | -11.56 | -34.32 | -23.28 | -56.07 | -18.28 | -4.77 | -14.15 | -12.72 | 0.52 | |
|
Price/Earnings (P/E)
|
-202.27 | 322.93 | -255.15 | -264.12 | -484.00 | -967.44 | -865.09 | -291.42 | -429.60 | -178.36 | -546.93 | -2,098.68 | -706.57 | -785.90 | 19,133.47 | |
| Price/Earnings Growth (PEG) | 5.85 | -2.83 | 2.48 | -1.24 | 11.72 | -9.44 | 54.57 | -18.28 | -22.17 | -8.73 | 46.59 | -94.67 | -83.44 | 17.92 | -180.65 | |
|
Price/Book (P/B)
|
-83.27 | -37.54 | 22.62 | 306.97 | 247.45 | 673.71 | 536.13 | 635.79 | 759.74 | 1,287.29 | -139.88 | 1,155.22 | -189.07 | -104.90 | 1,510.63 | |
| Price/Tangible Book (P/TB) | -83.27 | -37.54 | 22.62 | 306.97 | 247.45 | 673.71 | 536.13 | 635.79 | 759.74 | 1,287.29 | -139.88 | 1,155.22 | -189.07 | -104.90 | 1,510.63 | |
| Price/Sales (P/S) | - - | - - | - - | 250,598.90 | 65,043.84 | 354,146.38 | 357,368.52 | 149,652.71 | 334,011.77 | 203,561.80 | 645,325.11 | 3,947,143.89 | 37,557.67 | 57,519.40 | 1,037.65 | |
|
Price/Cash Flow (P/CF)
|
-538.20 | -102.23 | -2,514.07 | -920.09 | -915.67 | -1,539.23 | -1,218.52 | -370.25 | -542.82 | -240.00 | -738.59 | -2,796.95 | -849.78 | -909.30 | -7,718.44 | |
| Price/Free CF (P/FCF) | -538.20 | -102.08 | -2,514.07 | -919.84 | -915.19 | -1,538.41 | -1,217.37 | -368.19 | -542.81 | -239.83 | -737.86 | -2,792.31 | -848.63 | -909.23 | -7,718.44 | |
| Price/Operating CF (P/OCF) | -538.20 | -102.23 | -2,514.07 | -920.09 | -915.67 | -1,539.23 | -1,218.52 | -370.25 | -542.82 | -240.00 | -738.59 | -2,796.95 | -849.78 | -909.30 | -7,718.44 |